At a moment when nephrology is experiencing one of its most rapid periods of therapeutic evolution, American Society of Nephrology (ASN) Kidney Week 2025 arrived in Houston, Texas as both an opportunity for reflection of extraordinary progress and a preview of what may soon redefine care further. The past year alone has seen long-awaited FDA approvals in IgA nephropathy (IgAN) and C3 glomerulopathy, alongside expanding evidence for upstream immune-targeted strategies that are reshaping expectations for disease modification. With an anticipated regulatory decision in FSGS on the horizon in early 2026, the field is entering a new era marked by unprecedented mechanistic diversity and clinical ambition.
